SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: Longitudinal study

Background Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic in young children. Therefore, the true rate of infection is likely underestimated. Few data are available on the rate of infections in young children, and studies on the SARS-CoV-2 seroprevalence among children during omicron wave are limited. Our study aims to assess the SARS-CoV-2 infection-induced seroprevalence among children and estimated the associated risk factors for seropositivity. Methods A longitudinal serological survey was conducted from January 2021 through November 2022. Samples were tested for anti-nucleocapsid (N) IgG, anti-receptor binding domain (RBD) IgG using a chemiluminescent microparticle immunoassay (CMIA) and detected anti-RBD Immunoglobulin (Ig) using an electrochemiluminescence immunoassay (ECLIA). The vaccination and SARS-CoV-2 infection history were collected. Results A total of 452 serum samples were obtained from 249 children aged 5-7 years old who were annually followed-up in the longitudinal serological survey. Of these, 191 participants provided samples at two serial time points, including during the pre-and omicron dominant wave. Overall, seroprevalence induced by SARS-CoV-2 infection was increased from 9.1% (95%CI: 0.6-12.6%) during the pre-omicron wave to 49.7% (95%CI: 35.9-66.8%) during the omicron wave. Amongst seropositive individuals, the infection-induced seroprevalence was lower in vaccinated participants than those with no vaccination (40.4% vs. 57.4%; risk ratio, 0.71; 95%CI: 0.52-0.95). Nevertheless, the ratio of seropositive cases per recalled infection was 1.56 during the omicron dominant wave. In addition, overall seroprevalence induced by infection, vaccination and hybrid immunity was 76.6% (151/197; 95%CI: 54.6-97.9%) between January and November 2022. Conclusions our study reports an increase in infection-induced seroprevalence among children during the omicron wave. These findings highlight that estimating seroprevalence is crucial to monitor SARS-CoV-2 exposure, particularly in asymptomatic infection, and help to optimize public health policies and determine the effect of immunization in the pediatric population.

is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283006 doi: medRxiv preprint 4 66 Introduction 67 Most children with SARS-CoV-2 infection are asymptomatic at presentation. Thus, 68 mildly symptomatic and asymptomatic children might not be tested for or diagnosed with SARS-69 CoV-2 infection [1]. As a result, pediatric COVID-19 cases are underestimated and likely higher is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022.  231 We further estimated the overall seroprevalence induced by natural infection, vaccination 232 and hybrid immunity based on the seropositivity of anti-RBD antibodies (Fig 3). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283006 doi: medRxiv preprint 15 249 aged between 5 and 11 years [13]. In addition, our study showed that vaccinated children with 250 two-dose vaccines were less likely to be seropositive than those who were vaccinated with a 251 single dose. This result was supported by a meta-analysis study that suggested that the estimated 252 mean secondary attack rates observed during the omicron wave were higher in partially 253 vaccinated cases (76.8%, 95%CI: 7.7%-99.2%) than in fully vaccinated cases (50.8%, 95%CI: 254 47.9%-53.8%) [14].

255
Although an increased number of household members did not affect the risk of 256 seropositivity in children, we found a higher risk of seropositivity was observed in children 257 living with infected household members than those living with non-infected household members.
258 This finding was consistent with a study from Switzerland that indicated the risk of being 259 seropositive in children aged <6 years was more likely associated with the number of household . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted December 5, 2022.

294
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

317
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283006 doi: medRxiv preprint 4. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al.

340
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283006 doi: medRxiv preprint